Insider · CIK 0001282930
Carl L Gordon
directorowner
Files at KROS (Keros Therapeutics, Inc.), CMPX (Compass Therapeutics, Inc.), MBX (MBX Biosciences, Inc.), ADRX (ADARx Pharmaceuticals, Inc.), Lomond Therapeutics Holdings, Inc., ETRA (Electra Therapeutics, Inc.). First filing Feb 19, 2025, latest Sep 30, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
3 / 1
$38M bought, $5.7M sold
Where the trades landed
Last year at the 3 companies this insider has traded most, with each buy and sell on the bar it happened.
ADRX: ADARx Pharmaceuticals, Inc.
ADRXOct 9, 2026 · close 17.78
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
ETRA: Electra Therapeutics, Inc.
ETRAOct 9, 2026 · close 9.04
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
CMPX: Compass Therapeutics, Inc.
CMPXOct 9, 2026 · close 0.99
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | ADARx Pharmaceuticals, Inc. | $16M 950,000 shares | +7% | - | |
| 54Moderate | Electra Therapeutics, Inc. | $20M 1,333,333 shares | +28% | - | |
| 68Notable | Compass Therapeutics, Inc. | $5.7M 3,571,428 shares | -100% | +30% from low-55% from high | |
| 51Moderate | MBX Biosciences, Inc. | $2.0M 190,672 shares | +6% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +10,690,530 | - | - | 10,690,530 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +2,000,962 | - | - | 12,691,492 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +769,601 | - | - | 13,461,093 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +564,187 | - | - | 14,025,280 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +300,249 | $17.00 | $5.1M | 14,325,529 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +7,127,019 | - | - | 7,127,019 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +1,333,975 | - | - | 8,460,994 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +513,067 | - | - | 8,974,061 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +256,448 | - | - | 9,230,509 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +61,516 | $17.00 | $1.0M | 9,292,025 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +588,235 | $17.00 | $10.0M | 588,235 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -10,690,530 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -2,000,962 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -769,601 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -564,187 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -7,127,019 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,333,975 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -513,067 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -256,448 | $0.00 | $0 | 0 | 12 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +2,002,310 | - | - | 2,002,310 | 19 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +1,087,934 | - | - | 3,090,244 | 19 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +1,703,314 | - | - | 4,793,558 | 19 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +333,333 | $15.00 | $5.0M | 5,126,891 | 19 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +758,279 | - | - | 758,279 | 19 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +1,000,000 | $15.00 | $15M | 1,758,279 | 19 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnotes | -2,002,310 | $0.00 | $0 | 0 | 19 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnotes | -1,087,934 | $0.00 | $0 | 0 | 19 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Series C Convertible Preferred Stockderivativeindirect: See footnotes | -1,703,314 | $0.00 | $0 | 0 | 19 d ago |
| Sep 21, 2026 | ETRA Electra Therapeutics, Inc. | CConversion Series C Convertible Preferred Stockderivativeindirect: See footnotes | -758,279 | $0.00 | $0 | 0 | 19 d ago |
| Nov 21, 2025 | KROS Keros Therapeutics, Inc. | DDisposition to issuer Common Stockindirect: See footnotes | -140,057 | $17.75 | $2.5M | 759,155 | Dec 18, 2025 |
| Nov 21, 2025 | KROS Keros Therapeutics, Inc. | DDisposition to issuer Common Stockindirect: See footnotes | -74,465 | $17.75 | $1.3M | 45,057 | Dec 18, 2025 |
| Jun 4, 2025 | KROS Keros Therapeutics, Inc. | AGrant or award Common Stock | +5,250 | $0.00 | $0 | 5,250 | Jun 6, 2025 |
| Jun 4, 2025 | KROS Keros Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,500 | $0.00 | $0 | 10,500 | Jun 6, 2025 |
| Apr 9, 2025 | CMPX Compass Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnotes | -3,571,428 | $1.59 | $5.7M | 0 | Apr 11, 2025 |
| Feb 14, 2025 | MBX MBX Biosciences, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +17,962 | $9.90 | $178k | 3,176,390 | Feb 19, 2025 |
| Feb 14, 2025 | MBX MBX Biosciences, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +29,540 | $9.85 | $291k | 3,205,930 | Feb 19, 2025 |
| Feb 18, 2025 | MBX MBX Biosciences, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +49,070 | $10.84 | $532k | 3,255,000 | Feb 19, 2025 |
| Feb 18, 2025 | MBX MBX Biosciences, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +94,100 | $10.84 | $1.0M | 747,887 | Feb 19, 2025 |
| Feb 11, 2025 | CMPX Compass Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Feb 13, 2025 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Common Stockindirect: See Footnote | +323,916 | $3.20 | $1.0M | 323,916 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Common Stockindirect: See Footnote | +215,146 | $3.20 | $688k | 539,062 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Common Stockindirect: See Footnote | +389,078 | $3.60 | $1.4M | 928,140 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Common Stockindirect: See Footnote | +230,753 | $3.60 | $831k | 1,158,893 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Common Stockindirect: See Footnote | +74,613 | $3.60 | $269k | 1,233,506 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | AGrant or award Common Stockindirect: See Footnote | +808,894 | $4.00 | $3.2M | 2,042,400 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | AGrant or award Common Stockindirect: See Footnote | +479,736 | $4.00 | $1.9M | 2,522,136 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | AGrant or award Common Stockindirect: See Footnote | +155,120 | $4.00 | $620k | 2,677,256 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Simple Agreement for Future Equityderivativeindirect: See Footnote | -323,916 | $0.00 | $0 | 0 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Simple Agreement for Future Equityderivativeindirect: See Footnote | -215,146 | $0.00 | $0 | 0 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Simple Agreement for Future Equityderivativeindirect: See Footnote | -389,078 | $0.00 | $0 | 0 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Simple Agreement for Future Equityderivativeindirect: See Footnote | -230,753 | $0.00 | $0 | 0 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Simple Agreement for Future Equityderivativeindirect: See Footnote | -74,613 | $0.00 | $0 | 0 | Nov 5, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.